LYELL IMMUNOPHARMA INC (LYEL)

Company Profile

Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2021-06-17. The firm's investigational therapies use the patient's own cells as the starting point to generate highly tumor-reactive, longer-lasting functional T cells with enhanced ability to resist exhaustion and kill cancer cells. Its technologies are designed to generate T cells with the ability to persist and self-renew while driving tumor cytotoxicity. Its two product candidates, LYL797 and LYL845, are in Phase I clinical development, and an additional product candidate, LYL119, is entering Phase I clinical development. The firm is also engaged in accelerating the development of IMPT-314, a dual-targeting CD19/20 chimeric antigen receptor (CAR) T-cell product candidate for hematologic malignancies, including B-cell non-Hodgkin lymphoma.

Company Info

LYELL IMMUNOPHARMA INC

201 Haskins Way, Suite 301

South San Francisco CALIFORNIA

P: 16506950677

CEO: Elizabeth Homans

Employees: 224

Website: https://lyell.com/